3. Roche’s next immuno-oncologycombo is a big bet on Tigit. Retrieved April 5, 2020, fromhttps://www.evaluate.com/vantage/articles/news/trial-results/roches-next-immuno-oncology-combo-big-bet-tigit. 4.https://clinicaltrials.gov. FYI:总结生物医药更多知识点,敬请关注公众平台「佰傲谷BioValley」...
AMG 757 is being evaluated in a phase 1 clinical trial in patients with relapsed/refractory SCLC (NCT03319940). We evaluated the efficacy and pharmacodynamic (PD) effects of AMG 757 in three preclinical models of SCLC that express DLL3. We used the LXFS 1129 patient-derived xenograft (PDX) ...
November 12, 2020 - AMG 757, a DLL3-directed, half-life extended bispecific T-cell engager (BiTE), was shown to have a feasible adverse effect (AE) profile in patients with small cell lung cancer (SCLC), according to interim results from a phase 1 clinical trial (NCT03319940...